aggregation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Vaginal discharge may indicate a vaginal infection by color and odor, or the resulting symptoms of discharge, such as irritation or burning. Abnormal vaginal discharge may be caused by STIs, diabetes, douches, fragranced soaps, bubble baths, birth control pills, yeast infection (commonly as a result of antibiotic use) or another form of vaginitis. While vaginitis is an inflammation of the vagina, and is attributed to infection, hormonal issues, or irritants, vaginismus is an involuntary tightening of the vagina muscles during vaginal penetration that is caused by a conditioned reflex or disease. Vaginal discharge due to yeast infection is usually thick, creamy in color and odorless, while discharge due to bacterial vaginosis is gray-white in color, and discharge due to trichomoniasis is usually a gray color, thin in consistency, and has a fishy odor. Discharge in 25% of the trichomoniasis cases is yellow-green. HIV/AIDS, human papillomavirus (HPV), genital herpes and trichomoniasis are some STIs that may affect the vagina, and health sources recommend safe sex (or barrier method) practices to prevent the transmission of these and other STIs. Safe sex commonly involves the use of condoms, and sometimes female condoms (which give women more control). Both types can help avert pregnancy by preventing semen from coming in contact with the vagina.
239Pu(16O,xn)255−xNo This reaction was first studied in 1958 at the FLNR. The team were able to measure ~8.8 MeV alpha particles with a half-life of 30 s and assigned to253,252,251102. A repeat in 1960 was unsuccessful and it was concluded the first results were probably associated with background effects.
With the expiration of many patents for blockbuster biologics between 2012 and 2019, the interest in biosimilar production, i.e., follow-on biologics, has increased. Compared to small molecules that consist of chemically identical active ingredients, biologics are vastly more complex and consist of a multitude of subspecies. Due to their heterogeneity and the high process sensitivity, originators and follow-on biosimilars will exhibit variability in specific variants over time. The safety and clinical performance of both originator and biosimilar biopharmaceuticals must remain equivalent throughout their lifecycle. Process variations are monitored by modern analytical tools (e.g., liquid chromatography, immunoassays, mass spectrometry, etc.) and describe a unique design space for each biologic. Biosimilars require a different regulatory framework compared to small-molecule generics. Legislation in the 21st century has addressed this by recognizing an intermediate ground of testing for biosimilars. The filing pathway requires more testing than for small-molecule generics, but less testing than for registering completely new therapeutics. In 2003, the European Medicines Agency introduced an adapted pathway for biosimilars, termed similar biological medicinal products. This pathway is based on a thorough demonstration of comparability of the product to an existing approved product.
==== General paleoanthropology ==== Cerrito, Burkart & van Schaik (2026) review the techniques used to extract information on life history from hominin fossils. Towle (2026) reviews longstanding issues in the systematics of hominins, including non-monophyly of at least the genus Australopithecus and mosaic trait distribution among hominin taxa, and proposes to subsume the genera Paranthropus and Australopithecus within the genus Homo. Begun (2026) reviews the fossil record of African apes and humans, and argues that the lack of hominin fossils from Africa from the interval between 13.5 and 6–7 million years ago might not simply be the result of incompleteness of the fossil record, and is potentially consistent with the origin of hominins in Eurasia and their dispersal into Africa after 7 million years ago. Gardner et al. (2026) study changes of body size throughout the evolutionary history of hominins, and interpret their finding as consistent with marked body mass increase in members of the genus Homo other than Homo habilis and Homo rudolfensis. A study on the morphological diversity of the femur and the humerus in extant hominids is published by Aramendi (2026), who interprets her findings as indicative of variable utility of different long bones for taxonomic indentification of hominin fossils, and as indicating that some of the variability observed in isolated or fragmentary hominin fossils might not be caused by presence of more than one taxon in the studied fossil material.
Sources: en.wikipedia.org
== Units == The SI unit of dynamic viscosity is the newton-second per metre squared (N·s/m2), also frequently expressed in the equivalent forms pascal-second (Pa·s), kilogram per meter per second (kg·m−1·s−1) and poiseuille (Pl). The CGS unit is the poise (P, or g·cm−1·s−1 = 0.1 Pa·s), named after Jean Léonard Marie Poiseuille. It is commonly expressed, particularly in ASTM standards, as centipoise (cP). The centipoise is convenient because the viscosity of water at 20 °C is about 1 cP, and one centipoise is equal to the SI millipascal second (mPa·s). The SI unit of kinematic viscosity is metre squared per second (m2/s), whereas the CGS unit for kinematic viscosity is the stokes (St, or cm2·s−1 = 0.0001 m2·s−1), named after Sir George Gabriel Stokes. In U.S. usage, stoke is sometimes used as the singular form. The submultiple centistokes (cSt) is often used instead, 1 cSt = 1 mm2·s−1 = 10−6 m2·s−1. 1 cSt is 1 cP divided by 1000 kg/m^3, close to the density of water. The kinematic viscosity of water at 20 °C is about 1 cSt. The most frequently used systems of US customary, or Imperial, units are the British Gravitational (BG) and English Engineering (EE). In the BG system, dynamic viscosity has units of pound-seconds per square foot (lb·s/ft2), and in the EE system it has units of pound-force-seconds per square foot (lbf·s/ft2). The pound and pound-force are equivalent; the two systems differ only in how force and mass are defined.
Some non-α-amino acids exist in organisms. In these structures, the amine group is displaced further from the carboxylic acid end of the amino acid molecule. Thus a β-amino acid has the amine group bonded to the second carbon away, and a γ-amino acid has it on the third. Examples include β-alanine, GABA, and δ-aminolevulinic acid.
==== Black People's Convention ==== In August 1971, Biko attended a conference on "The Development of the African Community" in Edendale. There, a resolution was presented calling for the formation of the Black People's Convention (BPC), a vehicle for the promotion of Black Consciousness among the wider population. Biko voted in favour of the group's creation but expressed reservations about the lack of consultation with South Africa's Coloureds or Indians. A. Mayatula became the BPC's first president; Biko did not stand for any leadership positions. The group was formally launched in July 1972 in Pietermaritzburg. By 1973, it had 41 branches and 4000 members, sharing much of its membership with SASO.
Sources: en.wikipedia.org
The molecular weight of prothrombin is approximately 72,000 Da. The catalytic domain is released from prothrombin fragment 1.2 to create the active enzyme thrombin, which has a molecular weight of 36,000 Da. Structurally, it is a member of the large PA clan of proteases. Prothrombin is composed of four domains; an N-terminal Gla domain, two kringle domains and a C-terminal trypsin-like serine protease domain. Factor Xa with factor V as a cofactor leads to cleavage of the Gla and two Kringle domains (forming together a fragment called fragment 1.2) and leave thrombin, consisting solely of the serine protease domain. As is the case for all serine proteases, prothrombin is converted to active thrombin by proteolysis of an internal peptide bond, exposing a new N-terminal Ile-NH3. The historic model of activation of serine proteases involves insertion of this newly formed N-terminus of the heavy chain into the β-barrel promoting the correct conformation of the catalytic residues. Contrary to crystal structures of active thrombin, hydrogen-deuterium exchange mass spectrometry studies indicate that this N-terminal Ile-NH3 does not become inserted into the β-barrel in the apo form of thrombin. However, binding of the active fragment of thrombomodulin appears to allosterically promote the active conformation of thrombin by inserting this N-terminal region.
The dyes are immobilized on the column matrix effectively, since usually the dyes link to a monochlorotriazine or dichlorotriazine ring (triazine dye). This type of dyes works especially well on a support matrix with hydroxyl group. The commonly used supporting matrix would be cross-linked agarose (sepharose), sephadex, polyacrylamide, and silica. An example for triazine linkage immobilization is Blue Sepharose, resulting from Cibacron blue FG3-A with monochlorotriazine covalently coupled with OH group of sepharose. This reaction form an ether linkage and also hydrogen chloride. C29H20ClN7O11S3 + C24H38O19 → C53H57N7O30S3 + HCl Cibacron Blue FG3-A + Sepharose → Blue Sepharose + HCl
This schedule is an approximation, as actual healing rates vary depending on when in an animal's annual hair-growth cycle the brand is applied. Complete healing and final brand appearance can take up to five months in animals branded during a winter phase of hair growth and in as little as one or two months on animals with spring coats.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
Reversed-phase high-performance liquid chromatography is the standard approach, separating the main peak from related impurities. Ultraviolet detection near 214 nanometers captures the peptide backbone. Mass spectrometry is then used alongside chromatography to confirm identity and detect covalent modifications.